ENGN

enGene is a clinical-stage genetic-medicine company whose entire value rests on one asset: detalimogene (EG-70) for non-muscle-invasive bladder cancer. The 10-K is explicit that the firm 'currently only have one product candidate...in clinical development' and that failure or delay 'will be materially harmed,' making this 'riskier than similar companies that have multiple product candidates.' There is no revenue in any year shown (FY2022–FY2025 revenue is blank), and net loss widened to -$117M in FY2025 from -$55M the prior year, driven by R&D that jumped 146.6% to $94.5M. This is not a business you can value on fundamentals — it is a probability-weighted bet on a single Phase clinical readout against well-funded competitors (CG Oncology, Ferring, Merck's BCG, J&J, Pfizer, UroGen), all named in the filing as having 'significantly greater financial resources.'

The balance sheet is the one nuance that keeps this from being a zero-conviction avoid. Liabilities/equity is a modest 0.32x and current assets of $201M against current liabilities of $32M leave ~$169M of net current assets — above the ~$119M market cap (67.0M shares × $1.78). But that cushion is being consumed fast: operating cash flow was -$99.2M, cash and equivalents fell 71% to just $50.2M, and current liabilities more than doubled (+118%). Management's own MD&A flags the Hercules Loan Agreement and warns that further raises may force it to 'relinquish certain valuable rights' or 'significantly delay, scale back or discontinue' development — the language of a company that must raise dilutive capital soon. Shares already grew 31.4% year-over-year, and accumulated deficit sits at -$372M.